Hepatitis C


Hepatitis C

SCROLL DOWN

Hepatitis C


Hepatitis C

150 MILLION

The number of people worldwide chronically infected with the Hepatitis C virus (HCV).

Currently available therapies for HCV, while safe and effective, often require months of therapy and can still fail, resulting in a more difficult to cure, drug resistant virus. Riboscience is developing a simple regimen with improved efficacy, higher barrier to resistance and shorter treatment duration for all Hepatitis C infections.

The dual nucleoside therapy in development by Riboscience, RBS-1154 combined with RBS-1049, has the potential to be the shortest, most potent, and most forgiving treatment for HCV.

Influenza


Influenza

Influenza


Influenza

200 THOUSAND

The number of people hospitalized each year in the USA due to influenza related complications

Currently available antiviral treatments have limited efficacy and are threatened by treatment induced and naturally occurring drug resistance, which is of particular concern in the event of severe, life threatening infections.

The influenza nucleoside analog in development by Riboscience, RBS-3165, has the potential to be the most highly efficacious therapy for flu, with broad spectrum activity against all influenza strains, including pandemic (e.g. H1N1 “Swine Flu”) and emergent (e.g. “Bird Flu”) strains. 

RSV


Respiratory Syncytial Virus

RSV


Respiratory Syncytial Virus

200 THOUSAND

The number of people hospitalized each year in the USA due to respiratory syncytial virus (RSV).

In the US, RSV is the number one cause of pneumonia among infants less than 1 year old. RSV is also a significant cause of death among the elderly and the immunocompromised. There is no effective treatment for RSV.

The RSV nucleoside analog in development by Riboscience, RBS-3149, has the potential to be the most simple, safe and efficacious therapy for children and adults with RSV. 

Tropical Disease


Neglected Tropical Disease

Tropical Disease


Neglected Tropical Disease

500 Thousand 

The number of people with severe dengue who require hospitalization each year.

According to the World Health Organization (WHO), neglected tropical diseases (NTD) affect more than 1 billion people worldwide.  Many of these NTD's are viral infections that could be cured or prevented using nucleoside analogs.  Dengue is now common in more than 100 countries with highest prevalence in the Americas, South-East Asia and Western Pacific regions.  Severe dengue (previously known as dengue hemorrhagic fever) has become a leading cause of hospitalization and death among children and adults in these regions.  

In partnership with Government agencies, Riboscience is developing nucleoside analogs for the treatment of Dengue, Ebola, Chikungunya and Zika virus.